Blog
How risky is that biotech trial?
A framework to more methodically assess clinical development probability of success (POS).
When biotechs get breakthrough therapy status, Mr. Market yawns
As Jay-Z might say, breakthrough status may provide 99 benefits, but excess stock returns ain’t one.
Why Pharma Undervalues Novel R&D
New data on drug ramp rates could increase the financial attractiveness of “pioneer” projects.
Can Businesses Learn 'Superforecasting'? Easier Said Than Done
Business leaders should read Philip Tetlock's new book on analyzing data to predict the future - but whether they'll be able to implement its ideas is far from certain.
Making clinical development more investable with “financially adaptive trials”
Clinical trials are a terrible investment. But fear not – in our NRDD article, we show a path forward.
In defense of pharma forecasting
The problem isn't with Pharma forecasts – it's with how they're communicated and used in decision-making.